Paloma Partners’s Juno Therapeutics, Inc. JUNO Stock Holding History

Paloma Partners’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-11,500	Closed	-$344K	–	2668
2017 Q2	$344K	Buy	+11,500	New	+$284K	﹤0.01%	1746

Other funds holding JUNO

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Paloma Partners's JUNO Position: Q3 2017 in Review

Paloma Partners sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2017, closing a stake of 11,500 shares — an estimated $344K sold.

Paloma Partners first reported a position in JUNO in Q2 2017 and held it in 1 quarter. The position peaked at $344K in Q2 2017. 210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

Paloma Partners reported no remaining Juno Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
Paloma Partners sold 11,500 Juno Therapeutics, Inc. shares in Q3 2017, an estimated $344K.
Paloma Partners first reported a position in Juno Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
Paloma Partners's Juno Therapeutics, Inc. position peaked at $344K in Q2 2017.
210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.